BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ablitech, Inc. Awarded $2 Million


10/12/2011 10:37:24 AM

Hattiesburg, MS – Ablitech, Inc., a biotechnology company developing polymer-based delivery systems for gene silencing, today announced it has been awarded a $2 million grant by the U.S. Department of Defense (DoD).

Ken Malone, CEO of Ablitech, commented: “We are excited and grateful for DoD’s support and confidence in our technology and team. We will be working to provide long-term pain management research and develop new treatments in cooperation with the Army's Telemedicine and Advanced Technology Research Center (TATRC).”

The funds will be used to develop treatments for Heterotopic Ossification (HO). HO is a random painful bone growth that occurs after severe trauma such as amputation or concussion. Ablitech’s signature product, VersadelTM, will be used to deliver gene silencing (siRNA) that can selectively turn off unwanted cell growth.

“In early-2009 Ablitech approached TATRC with a new technology for gene silencing that turns off harmful cells such as cancer,” continued Malone. “TATRC requested Ablitech employ Versadel to address the problem of treating bone disorders associated with severe trauma.”

Malone ended, “The funds from the DoD and other federal grants, along with private investments, have enabled us to accelerate Versadel towards delivering on possibilities. The possibilities for curing cancer, HO and a broad range of other diseases.”

About Ablitech, Inc.:

Ablitech, Inc., founded in 2006, is a Hattiesburg, Mississippi-based company that draws from the latest advances in polymer science and medicinal chemistry. Ablitech develops radical technologies for healing the human body. Ablitech's flagship product line, VersadelTM, is a delivery system that overcomes the former hurdles of gene silencing. For more information regarding Ablitech, please visit www.ablitech.com, or contact Ken Malone at 601.466.7050 and ken.malone@ablitech.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->